Kumar, S., Warraich, M., Fatima, M., McCullough, K., Al-Kali, A., Alkhateeb, H. B., Begna, K., Mangaonkar, A. A., Saliba, A. N., Litzow, M. R., Hogan, W. J., Shah, M. V., Patnaik, M., Pardanani, A. D., Badar, T., Foran, J. M., Palmer, J. M., Yi, C. Y. A., Tefferi, A., Gangat, N. (2026). HMA plus venetoclax for 7- vs 14- vs 21- vs 28-day cycles in newly-diagnosed acute myeloid leukemia: ELN- and Mayo Genetic Risk–stratified analysis in 540 patients.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.6525